AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19735984 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women with estradiol serum concentrations in the cycling range
Number of subjects: 84
Study 19735984 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women with HRT
Number of subjects: 84
Study 19735984 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal women without HRT
Number of subjects: 84
Study 17065180 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) 20 mg thrice daily for 72 hours starting 48 hours before the procedure
Number of subjects: 82
Study 17065180 — intervention group
Group type: COMPARATOR
Intervention: Control group (isotonic saline infusion only)
Number of subjects: 82
Study 17065180 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ)
Number of subjects: 82
Study 17065180 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (TMZ) and isotonic saline infusion
Number of subjects: 82
Study 15862720 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased water intake
Number of subjects: 141
Study 15862720 — intervention group
Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 141
Study 11313831 — intervention group
Group type: EXPERIMENTAL
Intervention: IC351 (Cialis) 2 mg
Number of subjects: 179
Study 11313831 — intervention group
Group type: EXPERIMENTAL
Intervention: IC351 (Cialis) 5 mg
Number of subjects: 179
Study 11313831 — intervention group
Group type: EXPERIMENTAL
Intervention: IC351 (Cialis) 10 mg
Number of subjects: 179
Study 11313831 — intervention group
Group type: EXPERIMENTAL
Intervention: IC351 (Cialis) 25 mg
Number of subjects: 179
Study 11313831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 9461707 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic glomerulonephritis patients
Number of subjects: 46
Study 9461707 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 46
Study 7949227 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQA1 and HLA-DQB1 gene alleles
Number of subjects: 234
Study 7949227 — intervention group
Group type: EXPERIMENTAL
Intervention: DQA1 and DQB1 gene alleles
Number of subjects: 234
Study 3356771 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and bromocriptine
Number of subjects: 0
Study 3356771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31664719 — intervention group
Group type: EXPERIMENTAL
Intervention: Quilting closure (Q)
Number of subjects: 297
Study 31664719 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple continuous apposition (SC)
Number of subjects: 297
Study 31664719 — intervention group
Group type: COMPARATOR
Intervention: No subcutaneous closure (NC)
Number of subjects: 297
Study 30170401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (OA specimens)
Number of subjects: 80
Study 30170401 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (RA specimens with cement)
Number of subjects: 80
Study 30170401 — intervention group
Group type: COMPARATOR
Intervention: Group C (OA specimens with cement)
Number of subjects: 80
Study 27159505 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifapentine (approximately 7.5 mg/kg) plus moxifloxacin
Number of subjects: 121
Study 27159505 — intervention group
Group type: COMPARATOR
Intervention: Rifampin (approximately 10 mg/kg) plus ethambutol
Number of subjects: 121
Study 26232684 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair Skills Training Program (WSTP)
Number of subjects: 116
Study 26232684 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 116
Study 23902889 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 180
Study 20196977 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release carbamazepine capsules (ERCC)
Number of subjects: 0
Study 20196977 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release carbamazepine (IR)
Number of subjects: 0
Study 18221532 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/day
Number of subjects: 121
Study 18221532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 16755150 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 1 mg/day (increased to 2 mg/day and 4 mg/day) with a beta-blocker added after 1 month if needed
Number of subjects: 600
Study 16755150 — intervention group
Group type: COMPARATOR
Intervention: Control group (continued treatment as per enrollment)
Number of subjects: 600
Study 14584381 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) combined with a single dose of artesunate (AS)
Number of subjects: 1375
Study 14584381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1375
Study 10486449 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-Video
Number of subjects: 578
Study 10486449 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-Didactic
Number of subjects: 578
Study 10486449 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR-Social Support
Number of subjects: 578
Study 10486449 — intervention group
Group type: COMPARATOR
Intervention: Control (no CPR training)
Number of subjects: 578
Study 8759069 — intervention group
Group type: EXPERIMENTAL
Intervention: Poloxamer 188 (RheothRx) infusion for 48 hours
Number of subjects: 114
Study 1759572 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrinogenation (DF) therapy
Number of subjects: 168
Study 1759572 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone (BM) therapy
Number of subjects: 168
Study 6130558 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg clobazam
Number of subjects: 20
Study 6130558 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20
Study 31764011 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflationary NIBP measurement + cuff (YP‐71xT series)
Number of subjects: 30
Study 31764011 — intervention group
Group type: COMPARATOR
Intervention: Deflationary NIBP measurement + conventional cuff (control group)
Number of subjects: 30
Study 31764011 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflationary NIBP measurement + cuff (YP‐71xT series)
Number of subjects: 30
Study 29510352 — intervention group
Group type: EXPERIMENTAL
Intervention: affron® (saffron extract), 14 mg b.i.d
Number of subjects: 80
Study 27170466 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (1 mg/day)
Number of subjects: 44
Study 27170466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 24996648 — intervention group
Group type: EXPERIMENTAL
Intervention: Superion interspinous spacer (Experimental)
Number of subjects: 250
Study 24996648 — intervention group
Group type: COMPARATOR
Intervention: X-Stop interspinous spacer (Control)
Number of subjects: 250
Study 22045100 — intervention group
Group type: EXPERIMENTAL
Intervention: NEPP regimen (Nutrineal×1, Extraneal×1, Physioneal×2)
Number of subjects: 45
Study 22045100 — intervention group
Group type: COMPARATOR
Intervention: sPD regimen (conventional lactate‐buffered PDF)
Number of subjects: 45
Study 20538370 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based didactics
Number of subjects: 55
Study 20538370 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based teaching
Number of subjects: 55
Study 20538370 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 18711963 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension free vaginal tape (TVT)
Number of subjects: 288
Study 18711963 — intervention group
Group type: EXPERIMENTAL
Intervention: Transobturator suburethral tape (TVT O)
Number of subjects: 288
Study 16364834 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg, slow-release pill, administered 1 hour before bed for 3 weeks)
Number of subjects: 18
Study 16364834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered for 3 weeks)
Number of subjects: 18
Study 12055812 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ivermectin (150-200 micrograms/kg bodyweight) and albendazole (400 mg)
Number of subjects: 153
Study 12055812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 12055812 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 153
Study 12055812 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin
Number of subjects: 153
Study 12055812 — intervention group
Group type: COMPARATOR
Intervention: Combination of albendazole and ivermectin
Number of subjects: 153
Study 9872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine (personal history)
Number of subjects: 291
Study 9872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical migraine (with aura)
Number of subjects: 291
Study 9872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple migraine (without aura)
Number of subjects: 291
Study 9872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of migraine
Number of subjects: 291
Study 9872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine with coexistent oral contraceptive use, high blood pressure, or smoking
Number of subjects: 291
Study 9872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 291
Study 9872876 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine in women of childbearing age
Number of subjects: 291
Study 7726443 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 55
Study 7726443 — intervention group
Group type: COMPARATOR
Intervention: Face mask (FM)
Number of subjects: 55
Study 2325960 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly oxytocin infusion protocol
Number of subjects: 52
Study 2325960 — intervention group
Group type: COMPARATOR
Intervention: Quarter-hourly oxytocin infusion protocol
Number of subjects: 52
Study 7404129 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 50
Study 7404129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with primary hyperparathyroidism
Number of subjects: 50
Study 7404129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients on chronic haemodialysis
Number of subjects: 50
Study 7404129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypoparathyroidism
Number of subjects: 50
Study 7404129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with malignant disease
Number of subjects: 50
Study 7404129 — intervention group
Group type: EXPERIMENTAL
Intervention: Gut hormones (gastrin, secretin, CCK-PK)
Number of subjects: 50
Study 6363382 — intervention group
Group type: EXPERIMENTAL
Intervention: tobramycin + cefuroxime
Number of subjects: 21
Study 6363382 — intervention group
Group type: COMPARATOR
Intervention: tobramycin + penicillin G
Number of subjects: 21
Study 29680656 — intervention group
Group type: COMPARATOR
Intervention: Candida tropicalis added at 1 g/calf per day (CT)
Number of subjects: 15
Study 29680656 — intervention group
Group type: COMPARATOR
Intervention: Mulberry leaf flavonoids added at 3 g/calf per day (MLF)
Number of subjects: 15
Study 29680656 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 15
Study 27307271 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck collar (n=32)
Number of subjects: 62
Study 27307271 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=30)
Number of subjects: 62
Study 24115129 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg/week
Number of subjects: 324
Study 24115129 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 324
Study 23122801 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural myocardial infarction (MI) defined by CK-MB elevation of more than 3 times the upper limit of normal (ULN)
Number of subjects: 9087
Study 23122801 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous myocardial infarction (MI) defined by CK-MB more than twice the ULN
Number of subjects: 9087
Study 23122801 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural MI with CK-MB threshold of 27.7 times the ULN
Number of subjects: 9087
Study 23122801 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural MI in the SYNERGY study
Number of subjects: 9087
Study 23122801 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedural MI in the EARLY-ACS study
Number of subjects: 9087
Study 20352167 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal D-dimer
Number of subjects: 608
Study 20352167 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal D-dimer
Number of subjects: 608
Study 20352167 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 608
Study 20352167 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 608
Study 18599164 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 30 microg or 45 microg H5 HA adjuvanted formulations
Number of subjects: 800
Study 18599164 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 7.5 microg or 15 microg H5 HA (+/- AlPO4 adjuvant)
Number of subjects: 800
Study 18599164 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose offered 6 months after dose 2 (phase I trial only)
Number of subjects: 800
Study 18599164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype H5N1 vaccine
Number of subjects: 800
Study 16078599 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (5 mg/day for 12 weeks)
Number of subjects: 60
Study 16078599 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg/day for 12 weeks)
Number of subjects: 60
Study 16078599 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 60
Study 16078599 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with DM1 and DN
Number of subjects: 60
Study 12410741 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake
Number of subjects: 882
Study 12410741 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee consumption
Number of subjects: 882
Study 12410741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 882
Study 12410741 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index and professional education
Number of subjects: 882
Study 12410741 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 882
Study 10730559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine foam (Salofalk foam) 2 g twice a day
Number of subjects: 195
Study 10730559 — intervention group
Group type: COMPARATOR
Intervention: Mesalazine enema (2 g/60 ml twice a day)
Number of subjects: 195
Study 10730559 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to mesalazine foam after initial treatment with enema
Number of subjects: 195
Study 10730559 — intervention group
Group type: COMPARATOR
Intervention: Switch to mesalazine enema after initial treatment with foam
Number of subjects: 195
Study 7793583 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol emulsion containing 0.05% lignocaine
Number of subjects: 0
Study 7793583 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol emulsion containing lignocaine
Number of subjects: 0
Study 7793583 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of lignocaine above 0.05%
Number of subjects: 0
Study 1827568 — intervention group
Group type: EXPERIMENTAL
Intervention: E/CPA (1 mg cyproterone acetate)
Number of subjects: 139
Study 1827568 — intervention group
Group type: EXPERIMENTAL
Intervention: E/LNG (75 micrograms levonorgestrel)
Number of subjects: 139
Study 1827568 — intervention group
Group type: EXPERIMENTAL
Intervention: E/MPA (10 mg medroxyprogesterone acetate)
Number of subjects: 139
Study 1827568 — intervention group
Group type: EXPERIMENTAL
Intervention: E/DG (150 micrograms desogestrel)
Number of subjects: 139
Study 1827568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 6165750 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamber A (1000 PNU/ml ragweed extract)
Number of subjects: 8
Study 6165750 — intervention group
Group type: COMPARATOR
Intervention: Chamber B (buffered saline)
Number of subjects: 8
Study 6165750 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamber C (1000 PNU/ml ragweed and 50 ng histamine)
Number of subjects: 8
Study 6165750 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamber D (50 ng histamine)
Number of subjects: 8
Study 6165750 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of exogenous histamine (50 ng/ml) to ragweed before injection
Number of subjects: 8
Study 6165750 — intervention group
Group type: EXPERIMENTAL
Intervention: Ragweed alone (no histamine)
Number of subjects: 8
Study 30177585 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus cisplatin followed by maintenance pemetrexed (PC)
Number of subjects: 96
Study 30177585 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed monotherapy (P)
Number of subjects: 96
Study 29162123 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark blood late gadolinium enhancement (DB LGE)
Number of subjects: 172
Study 29162123 — intervention group
Group type: COMPARATOR
Intervention: Bright blood late gadolinium enhancement (bright blood LGE)
Number of subjects: 172
Study 26742388 — intervention group
Group type: COMPARATOR
Intervention: Liquid medication
Number of subjects: 26
Study 26742388 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-restricted medication
Number of subjects: 26
Study 23287846 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction (TRF) supplementation (150 mg/day) for 6 months
Number of subjects: 8
Study 23287846 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules for 6 months
Number of subjects: 8
Study 21687919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert calls
Number of subjects: 79
Study 18430685 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted implanted cortical electrical stimulation of the motor cortex with upper limb rehabilitation therapy
Number of subjects: 24
Study 18430685 — intervention group
Group type: COMPARATOR
Intervention: Rehabilitation therapy alone
Number of subjects: 24
Study 17201251 — intervention group
Group type: EXPERIMENTAL
Intervention: Aildenafil citrate 30 or 60 mg
Number of subjects: 250
Study 17201251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 12562652 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (ciprofloxacin and roxithromycin)
Number of subjects: 244
Study 12562652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study 11290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer intervention combining information from patient's medical record with general information about schizophrenia
Number of subjects: 112
Study 11290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Sessions with a community psychiatric nurse
Number of subjects: 112
Study 11290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention (first and last sessions with nurse and remainder with computer)
Number of subjects: 112
Study 11290639 — intervention group
Group type: COMPARATOR
Intervention: Nurse based education
Number of subjects: 112
Study 11290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer sessions
Number of subjects: 112
Study 11290639 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of interventions
Number of subjects: 112
Study 9412807 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily
Number of subjects: 574
Study 9412807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 574
Study 8214921 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 10
Study 8214921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3683061 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser surgery
Number of subjects: 60
Study 3683061 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (knife/electric knife)
Number of subjects: 60
Study 30304457 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dydrogesterone 30 mg daily
Number of subjects: 1034
Study 30304457 — intervention group
Group type: COMPARATOR
Intervention: 8% micronized vaginal progesterone (MVP) gel 90 mg daily
Number of subjects: 1034
Study 28265691 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986142 (5-900 mg single dose; 25-350 mg multiple doses, once daily for 14 days)
Number of subjects: 0
Study 28265691 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986142 (350 mg, once daily for 5 days)
Number of subjects: 0
Study 26666916 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramax (pyronaridine-artesunate combination)
Number of subjects: 349
Study 23531424 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-residue diet
Number of subjects: 230
Study 23531424 — intervention group
Group type: COMPARATOR
Intervention: Clear liquid diet
Number of subjects: 230
Study 23531424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 230
Study 21038171 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + CBT (n = 76)
Number of subjects: 147
Study 21038171 — intervention group
Group type: EXPERIMENTAL
Intervention: PT (n = 71)
Number of subjects: 147
Study 21038171 — intervention group
Group type: COMPARATOR
Intervention: UCC (n = 62)
Number of subjects: 147
Study 18514651 — intervention group
Group type: EXPERIMENTAL
Intervention: D(50)+E
Number of subjects: 92
Study 18514651 — intervention group
Group type: COMPARATOR
Intervention: NS+E
Number of subjects: 92
Study 16308253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate aqueous nasal spray (200 microg/day) for 3 months
Number of subjects: 35
Study 16308253 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 35
Study 12827312 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h elution (group A)
Number of subjects: 161
Study 12827312 — intervention group
Group type: COMPARATOR
Intervention: 24-h elution (group B)
Number of subjects: 161
Study 12827312 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-h elution (subgroup 1)
Number of subjects: 161
Study 12827312 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h elution (subgroup 3)
Number of subjects: 161
Study 10962855 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U calcitonin thrice a week for 3 months
Number of subjects: 41